Access to Zemaira
Putting patients in touch with Zemaira product samples
CSL Behring is committed to helping people with Alpha-1–associated emphysema
get the treatment they need. That's why we provide the Alpha-1 community with the
option of trying Zemaira for up to 2 weeks.* If you
are interested in this opportunity, please take the following steps to see if you
qualify:
- Speak with your doctor about the Zemaira sample program. If your doctor believes
Zemaira is right for you, he or she can submit the sample request
- Talk with your doctor to determine how and where you might receive infusions of
Zemaira
- Your doctor may need your help filling out any necessary forms for you to continue
taking Zemaira after the end of your trial period
If you have any questions or would like more information, please call
1-866-ZEMAIRA (1-866-936-2472).
If your doctor wants more information about obtaining samples of Zemaira or about other resources, tell him or her to visit
www.zemaira.com.
CSL Behring also provides other types of
financial support that can make getting Zemaira a little easier.
Important Safety Information
Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.
Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.
In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).
Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
Please see full prescribing information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.